Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intuitive Surgical, Inc. (ISRG) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer headquartered in Sunnyvale, California, Intuitive uses these filings to report financial results, material events, and other information relevant to shareholders and regulators.
Among the key documents available are current reports on Form 8-K. Recent 8-K filings include items reporting quarterly financial results under Item 2.02, where Intuitive furnishes press releases detailing revenue, procedure growth on its da Vinci surgical systems and Ion endoluminal system, and changes in the installed base of systems. Another 8-K filing reports a change in the role of a senior executive under Item 5.02, illustrating how the company discloses updates related to its leadership structure.
Investors also use Intuitive’s SEC filings to follow information that may appear in annual reports on Form 10-K and quarterly reports on Form 10-Q, such as risk factor discussions, descriptions of the company’s business and technologies, and summaries of regulatory and market conditions affecting robotic-assisted surgery and minimally invasive care. While these specific forms are not reproduced in the provided excerpts, they are part of the broader filing set accessible through the SEC’s EDGAR system.
On Stock Titan, ISRG filings are paired with AI-powered summaries designed to explain the content and context of complex documents. These tools can help readers understand the significance of earnings releases, regulatory updates, or governance changes without reading every line of each filing. Users can also review filings that relate to financial reporting, such as exhibits containing press releases, and monitor how Intuitive communicates procedure trends, system placements, and other operational metrics to the market.
For investors researching Intuitive’s regulatory history, this page serves as a focused entry point to the company’s SEC disclosures, including 8-Ks that reference earnings announcements and other material developments.
Intuitive Surgical executive Jamie Samath, EVP & CFO & Enterprise Technol, reported performance stock unit awards tied to prior grants. On January 28, 2026, 3,180 PSUs from a February 26, 2024 grant and 7,182 PSUs from a February 28, 2023 grant were credited after performance criteria were achieved.
The 2024 grant PSUs vest on February 26, 2027, and the 2023 grant PSUs vest on February 28, 2026, in each case subject to Samath’s continuous service to Intuitive Surgical through the respective third-anniversary vesting dates.
ISRG security holder Curet McAdams filed a Rule 144 notice to sell 126 shares of common stock through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $65,522.52. The shares were acquired on 01/29/2026 via a stock option exercise paid in cash.
The notice states 354,496,073 shares of common stock outstanding and an approximate sale date of 01/29/2026. Over the prior three months, Curet McAdams sold additional common shares in several transactions, each with disclosed share amounts and gross proceeds.
Intuitive Surgical EVP & Chief Medical Officer Myriam Curet reported option exercises and stock sales in Intuitive Surgical, Inc. common stock. On January 27, 2026, she exercised options for 105 shares at $229.39 and 125 shares at $208.90, then sold 105 shares and 125 shares at $532.61 per share.
The filing notes these trades occurred under a Rule 10b5-1 trading plan that expires on July 29, 2026. After these transactions, the report shows 251 and 1,362 non-qualified stock options remaining directly held and 353 common shares held indirectly by a trust.
Intuitive Surgical director Gary S. Guthart reported an option exercise and related share sales. On January 27, 2026, a non-qualified stock option for 25,500 shares was exercised at $174.2567 per share, increasing his directly held common stock to 28,194 shares.
That same day, 24,500 common shares held directly were sold at a weighted average price of $530.0981, leaving 3,694 directly held shares. In addition, 1,400 shares were sold from a trust for his daughter and 1,400 shares from a trust for his son, each at weighted average prices just above $531, with 15,720 shares remaining in each child’s trust and 1,231,890 shares indirectly held by a separate trust. The filing notes these transactions were carried out under a Rule 10b5-1 trading plan that expires on April 28, 2026.
A planned insider sale has been filed for ISRG common stock under Rule 144. The notice covers the proposed sale of 24,500 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $12,987,403.45 at the time of filing.
The shares to be sold were acquired on 01/27/2026 via a stock option exercise, paid in cash, involving the same 24,500 shares. The filing also shows that Gary S. Guthart sold 22,806 common shares on 12/01/2025 for $13,019,721.90 in gross proceeds during the prior three months.
A shareholder of ISRG has filed a notice of proposed sale under Rule 144 to sell 230 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares to be sold have an aggregate market value of $122,500.30, while 354,496,073 shares of the issuer’s common stock are reported as outstanding. The planned sale date is listed as 01/27/2026 on the NASDAQ market, and the shares were acquired on the same date via a stock option exercise paid in cash.
The filer also reports prior sales of the issuer’s common stock during the past three months, including a transaction on 10/28/2025 in which 7,562 shares were sold for $4,147,192.12 in gross proceeds. By signing, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s current or prospective operations.
A shareholder has filed a Form 144 indicating an intention to sell up to 2,800 shares of common stock through The Charles Schwab Corporation on the NASDAQ, with an aggregate market value of 1,488,269.00. The filing lists 354,496,073 shares of this class as outstanding, providing context for the planned sale. The shares to be sold were acquired on 12/03/2018 via a stock option exercise from the issuer, with payment made on the same date.
Intuitive Surgical, Inc. filed a current report stating that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release is furnished as Exhibit 99.1, giving investors access to the company’s quarterly performance details outside this report.
The company notes that the information contained in the report, including Exhibit 99.1, is being furnished rather than filed, meaning it is not subject to certain liability provisions under the Securities Exchange Act and is not automatically incorporated into other SEC filings. The report is signed on behalf of Intuitive by its Executive Vice President and Chief Financial Officer, Jamie E. Samath.
Intuitive Surgical, Inc. furnished a report stating that it has issued a press release with unaudited preliminary financial results for the fourth quarter and full year 2025. The release is provided as Exhibit 99.1.
The company also supplied additional unaudited preliminary revenue and procedure information in tabular form as Exhibit 99.2, which has been posted to the Investor Relations section of its website. The materials are designated as furnished rather than filed, meaning they are not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Intuitive Surgical, Inc. reported a leadership role change in its digital organization. Effective January 1, 2026, Brian E. Miller, Ph.D., will move from his current position as Chief Digital Officer to become Head of Digital and AI Strategy. In this new role, Dr. Miller will continue focusing on the company’s digital and artificial intelligence initiatives but will no longer report directly to the Chief Executive Officer. The filing does not describe additional changes to his responsibilities or to other executive roles.